Given that AMPK acts as an upstream effector of TAK1/NF-κB signaling, we next investigated whether targeting AMPK alone, or in combination with TAK1 suppression could inhibit the oncogenic capacities of ovarian cancer cells cultured in OCM. The gene discussed is PRKAA1; the disease is ovarian carcinoma.